U.S., July 10 -- ClinicalTrials.gov registry received information related to the study (NCT07057427) titled 'Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer' on June 24.

Brief Summary: The aim of this study is to evaluate the efficacy of nab-paclitaxel (on days 1 and 8 of a 21-day cycle) compared to the standard regimen of docetaxel plus carboplatin, both combined with trastuzumab and pertuzumab, as neoadjuvant therapies for HER2-positive breast cancer.

Study Start Date: June 24

Study Type: INTERVENTIONAL

Condition: Breast Cancer

Intervention: DRUG: Nab paclitaxel

Nab-paclitaxel (on days 1 and 8 of a 21-day cycle)

DRUG: Docetaxel and Carboplatin

Docetaxel 75 mg/m2(day 1) + Carboplatin ...